Extremely Low Frequency Electromagnetic Fields Prevent Chemotherapy Induced Myelotoxicity

Edoardo Rossi a, Maria Teresa Corsetti a, Samir Sukkar b, Claudio Poggi c

a Department of Haematology, University-Hospital San Martino, Genoa, Italy
b Department of Nutrition, University-Hospital San Martino, Genoa, Italy
c Studio Poggi, Taggia, Italy

Online Publication Date: 01 October 2007

To cite this Article: Rossi, Edoardo, Corsetti, Maria Teresa, Sukkar, Samir and Poggi, Claudio (2007) 'Extremely Low Frequency Electromagnetic Fields Prevent Chemotherapy Induced Myelotoxicity', Electromagnetic Biology and Medicine, 26:4, 277 - 281

To link to this article: DOI: 10.1080/15368370701761984
URL: http://dx.doi.org/10.1080/15368370701761984
Extremely Low Frequency Electromagnetic Fields Prevents Chemotherapy Induced Myelotoxicity

EDOARDO ROSSI¹, MARIA TERESA CORSETTI¹, SAMIR SUKKAR², AND CLAUDIO POGGI³

¹Department of Haematology, University-Hospital San Martino, Genoa, Italy
²Department of Nutrition, University-Hospital San Martino, Genoa, Italy
³Studio Poggi, Taggia, Italy

Side effects of chemo-radiotherapy reduce the quality and also the survivability of patients. The consequent fatigue and infections, related to myelodepression, act to reduce the dose-intensity of the protocol. Late side effects of chemo-radiotherapy include secondary tumors, acute myeloid leukemias and cardiotoxicity. Side effects of chemotherapy are related to oxidative stress produced by the treatment. Oxidative stress also reduces the efficacy of the treatment. Antioxidative treatment with natural (dietetif) or chemical agents has been reported to reduce the toxicity of chemo-radiotherapy and improve the efficacy of treatment. We here report our experience with SEQEX, an electromedical device that generates Extremely Low Frequency ElectroMagnetic Fields (ELF-EMF) to produce endogenic cyclotronic ionic resonance, to reduce myelotoxicity consequent to ABVD protocol in patients with Hodgkin’s lymphoma.

Keywords Antioxidative treatment; Chemo-radiotherapy; Hodgkin’s lymphoma; Ion cyclotron resonance; Myelotoxicity.

Introduction

In Hodgkin’s and non-Hodgkin’s Lymphoma chemotherapy may cure a high number of patients. Improvement of survival reveal tardive toxicity related to chemotherapy and radiotherapy which may appear also within a few decades after conclusion of treatment. Recently Dutch researchers (Aleman et al., 2003) compared the causes of death of over 1,200 patients with Hodgkin’s lymphoma with the normal population. They concluded that patients with Hodgkin’s lymphoma were at risk of excess deaths from secondary cancers and cardiovascular disease throughout

Address correspondence to Edoardo Rossi, Department of Haematology, University-Hospital San Martino, Genoa, Italy; E-mail: edoardo.rossi@hsanmartino.it
more than 30 years of follow-up. They estimated that the rate of death from all
causes other than HD was 6.8 times that of the general population.

Chemotherapy also induces a transient toxicity which may present during
the treatment and results in fatigue, impairment of the quality of life and
myelodepression. In particular myelodepression may reduce the dose-intensity
schedule, which may compromise the results of the treatment, requiring supportive
treatment with hematological growth-factors. It has been reported (Conklin, 2000;
Myers, 1998) that the “oxidative stress” consequent to treatment with chemotherapy
and radiotherapy is one of the factors responsible for chemo-radiotherapy-related
toxicity. Oxidative stress is the condition where “reactive oxygen species” (ROS)
that are created exceed the capacity of the anti-oxidant system to reduce them. The
consequence is an excess of ROS in cells and tissues. Toxicity of chemotherapy
is, at least in part, consequent to the production of ROS. ROS are responsible
of the mutagenesis induced by chemotherapy, which is one of its late side
effects (secondary tumor) (Martingale et al., 2002). Exposure of cellular DNA to
ROS induce accumulation of mutations whose end product is tumor production.
Anti-oxidative drugs such as amiphostine, dexraroaxane and trimetazidina are used
to reduce the toxicity of chemotherapy in particular cardio toxicity (Mantovani
et al., 2002; Pascale et al., 2002; Sparano, 1998).

Oxidative stress reduces the efficacy of many chemotherapeutic drugs because
it inhibits apoptosis, which is the therapeutic pathway of cell death of tumor cells
induced by chemotherapy (Kagan et al., 2002; Shacter et al., 2000). Anti-oxidants
on the other hand may improve the efficacy of chemotherapy. Multiple dietary
antioxidants and glutamine are efficacious not only to reduce the toxicity of
chemotherapy but also to improve its efficacy (Prasad, 2004; Savarese et al., 2003).

SEQEX is an electromedical apparatus which is able to produce 30 different
shapes of electromagnetic waves with intensities between 1 to 100 \( \mu \)T and a frequency
between 1 to 100 Hz (Extremely Low frequency ElectroMagnetic Fields [ELF-EMF]).
The shape, intensity and frequency of waves are selected by SEQEX on the basis
of the measurement of the impedance measured in the body of the subject under
treatment. In fact the body of the subject responds to every singular wave received
with a cellular ionic movement (endogenous cyclotronic ion resonance) measured by
changes in body impedance, and the waves which produces better ionic movement
are selected and saved in a memory card. Subsequently the waves selected, stored
digitally on this card, are used to treat the patient.

Recently Raggi et al. (in press) in work yet to be published reported
experimental data, conducted with SEQEX at Perugia University, clearly
demonstrating that this treatment is able to reduce oxidative stress in a population
of normal people.

These results prompted us: (1) to confirm the data about the potential for
SEQEX to reduce oxidative stress and (2) to investigate this property to reduce the
toxicity of ABVD chemotherapy. Typical dosages for one 28-day cycle of ABVD
are as follows

- **Adriamycin** 25 mg/m² IV on days 1 and 15
- **Bleomycin** 10 mg/m² IV on days 1 and 15
- **Vinblastine** 6 mg/m² IV on days 1 and 15
- **Dacarbazine** 375 mg/m² IV on days 1 and 15
The total number of cycles given depends upon the stage of the disease.
Our experimental design followed 18 patients receiving chemotherapy. Included were nine patients in Group 1 receiving ELF-EMF therapy, and nine patients in Group 2 not receiving ELF-EMF therapy.

Results

(1) We evaluated oxidative stress before and after 27 minutes of 38 SEQEX treatments using the FRAS-3 technique (Cornelli et al., 2001). Overall, the mean oxidative stress was 208.6 at the beginning of treatment and 168.5 at the end, as shown in Fig. 1. We also observed reductions of oxidative stress during the treatment in the majority of tests.

(2) An appropriate dose-intensity of drugs, in accordance with protocol, consists of obtaining maximal efficacy of treatment, measured in terms of percentage and duration of complete remission. In ABVD protocol the major obstacle to prescribing the administration of a correct dose-intensity of drugs is myelotoxicity. The administration of G-CSF attempts to overcome this possible complication. We calculated the dose of G-CSF to administer to patients on the basis of number of neutrophil count checked weekly during chemotherapy.

The median total dose of G-CSF administered during the first four courses of therapy to the patients of Group 1 receiving ELF-EMF treatment was 1200 mcg (range: 900–3900 mcg) while it was 5100 mcg (range: 1200–7500 mcg) for the patients of Group 2, the difference is statistically significant ($p = 0.0002$). Usually patients during treatment with ABVD complain of “fatigue”. Fatigue is related to the reduction of haemoglobin levels during chemotherapy and it is one of the causes responsible for the poor quality of life of such patients. We studied the difference between the haemoglobin value (Hb) at the beginning of therapy and the lower value during the four courses of chemotherapy. The median value of Hb reduction in Group 1 was 0.3 g/dl (range: 0–1.8 g/dl) while in Group 2 it was 1.4 g/dl (range: 0–3.2 g/dl) (not statistically significant, $p = 0.1$). These clinical data for the 18 patients, the G-CSF administered to each patient and the maximal reduction of Hb levels are reported in Table 1.

Figure 1. Evaluation of oxidative stress before and after 27 minutes of 38 SEQEX treatments as measured using the FRAS-3 technique.
Table 1

Patients 1 to 9 had supportive therapy with Seqex. Patients 10 to 18 in the second group did not. Age and stage are similar in the two groups. The G-CSF administered in the two groups is statistically different and is greater for those who did not receive the Seqex treatment. The group of patients not receiving the supportive treatment tended to have a larger decrease of haemoglobin, but this decrease was not statistically significant.

<table>
<thead>
<tr>
<th>Group</th>
<th>Age</th>
<th>Sex</th>
<th>Stage</th>
<th>G-CSF (µg) administered</th>
<th>Major Hb reduction (g/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>N° 1</td>
<td>42</td>
<td>F</td>
<td>II A</td>
<td>1200</td>
<td>0.9</td>
</tr>
<tr>
<td>N° 2</td>
<td>44</td>
<td>M</td>
<td>III A</td>
<td>1500</td>
<td>1.8</td>
</tr>
<tr>
<td>N° 3</td>
<td>45</td>
<td>M</td>
<td>II A</td>
<td>900</td>
<td>0</td>
</tr>
<tr>
<td>N° 4</td>
<td>69</td>
<td>M</td>
<td>I A</td>
<td>3900</td>
<td>0</td>
</tr>
<tr>
<td>N° 5</td>
<td>38</td>
<td>M</td>
<td>III A</td>
<td>1200</td>
<td>1.5</td>
</tr>
<tr>
<td>N° 6</td>
<td>35</td>
<td>F</td>
<td>II A</td>
<td>1200</td>
<td>0.5</td>
</tr>
<tr>
<td>N° 7</td>
<td>26</td>
<td>F</td>
<td>II A</td>
<td>1200</td>
<td>0.1</td>
</tr>
<tr>
<td>N° 8</td>
<td>39</td>
<td>F</td>
<td>III A</td>
<td>1200</td>
<td>0</td>
</tr>
<tr>
<td>N° 9</td>
<td>40</td>
<td>F</td>
<td>IV A</td>
<td>2400</td>
<td>0.6</td>
</tr>
<tr>
<td>Mean</td>
<td>40</td>
<td></td>
<td></td>
<td>1200</td>
<td>0.3</td>
</tr>
<tr>
<td>N° 10</td>
<td>47</td>
<td>F</td>
<td>III A</td>
<td>5100</td>
<td>3.2</td>
</tr>
<tr>
<td>N° 11</td>
<td>26</td>
<td>F</td>
<td>II A</td>
<td>5700</td>
<td>0.4</td>
</tr>
<tr>
<td>N° 12</td>
<td>20</td>
<td>M</td>
<td>III A</td>
<td>3600</td>
<td>0</td>
</tr>
<tr>
<td>N° 13</td>
<td>27</td>
<td>F</td>
<td>II A</td>
<td>1200</td>
<td>1.2</td>
</tr>
<tr>
<td>N° 14</td>
<td>78</td>
<td>F</td>
<td>II A</td>
<td>7500</td>
<td>2.7</td>
</tr>
<tr>
<td>N° 15</td>
<td>26</td>
<td>M</td>
<td>III A</td>
<td>4800</td>
<td>1.4</td>
</tr>
<tr>
<td>N° 16</td>
<td>40</td>
<td>M</td>
<td>II A</td>
<td>6600</td>
<td>1.6</td>
</tr>
<tr>
<td>N° 17</td>
<td>23</td>
<td>F</td>
<td>II A</td>
<td>5100</td>
<td>0</td>
</tr>
<tr>
<td>N° 18</td>
<td>43</td>
<td>M</td>
<td>I A</td>
<td>4500</td>
<td>1.6</td>
</tr>
<tr>
<td>Mean</td>
<td>27</td>
<td></td>
<td></td>
<td>5100</td>
<td>1.4</td>
</tr>
</tbody>
</table>

Conclusion

SEQEX through its production of selective ELF-EMF signals is able to reduce the oxidative stress. This may reduce the side effects of chemotherapy, specifically myelodepression. We know that oxidative stress may be, at least in part, responsible for secondary malignancies and cardiovascular diseases consequent to radio-chemotherapy, so we conclude that this medical device which reduces oxidative stress induced by treatment with chemo-radiotherapy may reduce the risk of these late toxicities.

We also conclude that the use of SEQEX in combination with a diet rich in anti-oxidant agents may further improve these results. We are involved in ongoing studies to find a protocol to prove the efficacy of such association as a supportive treatment for patients with Hodgkin and non-Hodgkin disease who are candidates for chemotherapy.
References


